Skip to main content

Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review


A biomarker describes a measurable indicator of a patient's clinical condition that can be measured accurately and reproducibly. Biomarkers offer utility for diagnosis, prognosis, early disease recognition, risk stratification, appropriate treatment (theranostics), and trial enrichment for patients with sepsis or suspected sepsis. In this narrative review, we aim to answer the question, "Do biomarkers in patients with sepsis or septic shock predict mortality, multiple organ dysfunction syndrome (MODS), or organ dysfunction?" We also discuss the role of pro- and anti-inflammatory biomarkers and biomarkers associated with intestinal permeability, endothelial injury, organ dysfunction, blood–brain barrier (BBB) breakdown, brain injury, and short and long-term mortality. For sepsis, a range of biomarkers is identified, including fluid phase pattern recognition molecules (PRMs), complement system, cytokines, chemokines, damage-associated molecular patterns (DAMPs), non-coding RNAs, miRNAs, cell membrane receptors, cell proteins, metabolites, and soluble receptors. We also provide an overview of immune response biomarkers that can help identify or differentiate between systemic inflammatory response syndrome (SIRS), sepsis, septic shock, and sepsis-associated encephalopathy. However, significant work is needed to identify the optimal combinations of biomarkers that can augment diagnosis, treatment, and good patient outcomes.


A biomarker describes a measurable indicator of biological status in normal and pathogenic processes. It may be helpful as a theranostic for identifying suitable patients for therapeutic intervention and titrating the degree and/or duration of intervention. A biomarker should be accurate and reproducible. In the ideal scenario, the biomarker (or combination of biomarkers) should offer both high specificity and sensitivity for diagnosing a condition, but either alone may be adequate as a 'rule-in' or 'rule-out' test.

Sepsis represents a dysregulated immune response to infection that leads to organ dysfunction [1]. Host response biomarkers play a critical role in diagnosis, early recognition of organ dysfunction, risk stratification, prognostication, and patient management, including antibiotic stewardship. Biomarkers may also be helpful for trial enrichment to identify suitable patients and/or risk categorization for an intervention. A wide range of biomarkers, measured by a host of different technologies, are being investigated to discriminate a systemic inflammatory response syndrome (SIRS) rapidly, which is an excessive defensive body's response to a harmful stressor (for example, infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or cancer) [2] or early identification of infection-triggered organ dysfunction (sepsis). Also, the quick sepsis related organ failure assessment (qSOFA) is intended to raise suspicion of sepsis and encourage additional action; although, qSOFA is not a substitute for SIRS [3]. These biomarkers include measurement of acute-phase proteins, cytokines, chemokines, damage-associated molecular patterns (DAMPs), endothelial cell markers, leukocyte surface markers, non-coding RNAs, miRNA, and soluble receptors, as well as metabolites and alterations in gene expression (transcriptomics). Biomarkers may help stratify septic patients into biological phenotypes, for example, hyperinflammatory versus immunosuppressive. Biomarkers can also be used to identify gut permeability, blood–brain barrier (BBB) permeability, probability of hospital readmission, and longer-term outcomes [4, 5].

The causative pathogen replicates and releases its constituents such as endo- and exotoxins, and DNA. These constituents are designated pathogen-associated molecular patterns (PAMPs) [6, 7]. PAMPs are recognized by both pattern-recognition receptors (PRRs) and non-PRRs, which are essential components of the immune system [8, 9]. PRRs include several families, including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NOD)-like receptors (NLRs), a retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs), and intracellular DNA-sensing molecules. Non-PRRs include receptors for advanced glycation end products (RAGE), triggering receptors expressed on myeloid cells (TREM), and G-protein-coupled receptors (GPCRs) [10]. The sensing of PAMPs by immune cell receptors triggers a cascade of signaling pathways that activate multiple transcription factors to promote the production and release of pro- and anti-inflammatory mediators such as acute-phase proteins, cytokines, chemokines, as well as antimicrobial peptides, which are needed to eliminate the invading pathogen [11].

The host immune response and pathogen virulence factors will both trigger cell injury and/or induce cell stress. These results in the release of endogenous molecules (DAMPs), exacerbating the inflammatory response. DAMPs are recognized by the same immune receptors that recognize PAMPs [12, 13]. Many DAMPs have been identified, with some currently used as inflammatory biomarkers. Examples include proteins and cellular molecules related to nucleic acids, such as heat shock proteins (HSPs), the high mobility group box 1 (HMGB-1), and members of the S100 family [12, 14, 15]. The immune response may induce vascular endothelial damage disrupting tight junctions (T.J.), increasing gut permeability, and potentially facilitating translocation of pathogens and/or their PAMPs from the gut to the bloodstream and lymphatics, thereby amplifying the systemic inflammatory response [16]. In addition, an increase of BBB permeability allows circulating immune cells to enter the brain, triggering or exacerbating glial cell activation [17]. These events could trigger an intense and excessive host response activating coagulation and fibrinolytic systems, activating or suppressing hormonal, bioenergetic, and metabolic pathways, and inducing macro- and microcirculatory changes with a net result of multiple organ dysfunction. In the past few decades, researchers have studied each inflammatory response stage during SIRS, sepsis, and septic shock, metabolites associated with inflammatory cascades, and cellular components that could be used as biomarkers. These biomarkers could help identify endothelial damage, intestinal permeability, organ failure, BBB breakdown and predict rehospitalization, short- and long-term mortality, and cognitive consequences in survivors [18].

For this narrative review, we addressed the question, "Do biomarkers in patients with sepsis or septic shock predict mortality, MODS, or organ dysfunction?" Studies were identified by searching PubMed/MEDLINE (National Library of Medicine) databases for peer-reviewed journal articles published until October 2021. The abovementioned databases were searched with the following combinations of keywords: ("inflammatory response syndrome" OR "SIRS" OR "sepsis" OR "septic shock" OR "sepsis-associated encephalopathy" OR "SAE") AND ("markers" OR "biomarkers" OR "biological markers" OR "biological measures" OR "molecular predictor"). We omitted review articles, in vitro studies, and animal studies.

The humoral innate immune response, cytokines, and chemokines

The humoral innate immune response consists of multiple components, including fluid phase pattern recognition molecules (PRMs) and the complement system. PRMs include C-reactive protein (CRP), serum amyloid P component (SAP), and pentraxin 3 (PTX-3) [19]. The rise in CRP level is primarily induced by interleukin (IL)-6 and IL-1β acting on the gene responsible for CRP transcription during the acute phase of an inflammatory process. CRP is a pentameric acute-phase reactant protein whose conformation facilitates the ability to trigger complement activation and activate platelets, monocytes, and endothelial cells [20]. Furthermore, CRP is one of the most widely used and investigated biomarkers [21]. A prospective multicenter cohort study followed 483 adult patients who survived hospitalization for sepsis for up to one year. IL-6, high-sensitivity C reactive protein (hs-CRP), soluble programmed death-ligand 1 (sPD-L1), E-selectin, and intercellular adhesion molecule 1 (ICAM-1) were evaluated at five-time points during and after hospitalization. A comparison was made between a phenotype with hyperinflammation (high levels of IL-6 and hs-CRP) and a phenotype of immunosuppression (high sPD-L1 levels). Compared with a normal phenotype, both hyperinflammation and immunosuppression phenotypes had higher 6-month hospital readmission rates and 1-year mortality rates, both all-cause and attributable to cardiovascular or cancer [22].

Pentraxin (PTX-3) is secreted by macrophages, dendritic cells, macrophages, fibroblasts, mesangial cells, and glial cells under pathogen or inflammatory stimuli [19]. Plasma PTX-3 was assessed on days 1, 2, and 7 in 958 patients with sepsis or septic shock included in the Albumin Italian Outcome Sepsis (ALBIOS) study. The researchers assessed a possible association between PTX-3 levels and clinical severity, organ dysfunction, treatment, and mortality within 90 days. PTX-3 levels were elevated at the onset of sepsis and increased with illness severity and the number of organ dysfunctions. PTX-3 levels decreased between days 1 to 7, but this was less prominent in patients with septic shock [23]. In a prospective observational analysis, PTX-3, IL-6, procalcitonin (PCT), and lactate combined showed excellent performance in predicting 28-day all-cause mortality among patients diagnosed with sepsis or septic shock and superior to the Sequential Organ Failure Assessment (SOFA) score [24].

In a prospective pilot study of markers of complement activation in sepsis, higher C4d (3.5-fold), factor Bb (6.1-fold), C3 (0.8-fold), C3a (11.6-fold), and C5a (1.8-fold) levels were seen compared with healthy volunteer controls [25]. In another study of 49 sepsis patients, 34 developed disseminated intravascular coagulation (DIC), and eight died. Patients with DIC had lower C3 levels and higher SC5b-9 levels. On stratifying by SC5b-9 quartile (ng/mL: low: < 260, moderate: 260–342, high: 343–501, highest: > 501), coagulation parameters were most deranged in the highest quartile with prolonged thrombocytopenia and higher mortality (33%) [26].

The activation of PRRs culminates in the stimulation of transcription factors resulting in the expression and secretion of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), IL-1-β, IL-6, and interferons (IFNs). These inflammatory mediators are required for host defense against pathogens and activation of the adaptive immune response. A retrospective study evaluated a broad panel of cytokines and found IL-1β, IL-6, IL-8, MCP-1, IL-10, and plasminogen activator inhibitor 1 (PAI-1) levels were increased in the acute phase of sepsis in both critically and non-critically ill patients. In addition, levels of IL-10 (days 1, 2, and 4), IL-6 and PAI-1 (days 2 and 4), and IL-8 (day 4) increased in critically ill patients compared to non-critically ill [27]. In summary, hs-CRP, IL-6, and PAI-1 circulatory levels may have utility in stratifying a hyperinflammatory patient phenotype.


DAMPs are endogenous danger molecules released from damaged or stressed cells. These molecules activate the innate immune system through interaction with PRRs. DAMPs contribute to the host defense but can also promote pathological inflammatory responses. Calprotectin, a protein found in the cytosol of neutrophils and macrophages, is released under cell stress or damage. In a mixed population study, plasma calprotectin levels were higher in sepsis than in trauma patients and other medical conditions. Calprotectin levels were higher in patients who did not survive for 30 days. Plasma PCT did not differ between the groups or as a prognosticator of the outcome. Receiver operating characteristic (ROC) analysis, used as a sepsis biomarker, had a higher area under the curve (AUC) value for calprotectin (AUC: 0.79) compared to PCT (AUC: 0.49) [28].

A prospective study evaluated IL-6, HMGB-1, and neutrophil gelatinase-associated lipocalin (NGAL) in 14 septic patients and 16 patients without sepsis admitted to the ICU. In patients with sepsis, IL-6 decreased levels were associated with ICU survival; NGAL levels rose in non-survivors, while HMGB-1 levels were unchanged in both survivors and non-survivors regardless of complications [29].

Endothelial cells and BBB markers

The first step in endothelial and BBB injury is the breakdown and destruction of proteins followed by release into the bloodstream. These proteins or peptides can be evaluated as a marker of endothelial cells and BBB integrity [30]. Plasma levels of occludin (OCLN), claudin-5 (CLDN-5), zonula-occludens 1 (ZO-1), PCT, and lactate were assessed in 51 septic patients. OCLN and ZO-1 were elevated with disease severity and positively correlated with the Acute Physiology and Chronic Health Evaluation II (APACHE-II) and SOFA scores and lactate levels. The predictive value for in-hospital mortality of ZO-1 was comparable to that of lactate levels, APACHE-II, and SOFA scores but superior to OCLN and PCT [31]. In a case series of brain autopsies from adults who died from sepsis, 38% had no OCLN expression in the endothelium of cerebral microvessels. BBB damage was associated with higher maximum SOFA scores and PCT levels > 10 μg/L. BBB damage in the cerebellum was more common with CRP values > 100 mg/L [32]. Soluble fms-like tyrosine kinase 1 (sFlt-1), soluble E-selectin (sE-selectin), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1 (sVCAM-1), and PAI-1 were evaluated in another studies. All these evaluated endothelial biomarkers were associated with sepsis severity. sFlt-1 had the strongest association with the SOFA score, while sFlt-1 and PAI-1 had the highest area under the operating receiver characteristic curve for mortality [33].

Syndecan-1 is a structural component of the endothelium. Antithrombin, PAI-1, syndecan-1, VCAM-1, E-selectin, IL-1β, IL-6, IL-8, HMGB-1, and histone-H3 were increased in septic patients compared with healthy controls. Non-survivors had a higher syndecan-1 level compared with survivors. On day one, an association was seen between syndecan-1 levels and APACHE-II, SOFA, DIC scores, hemostatic markers, IL-1β, IL-8, and PAI-1. Day 1 syndecan-1 levels were also significantly higher in patients with DIC and had reliable discriminative power to predict both DIC development and subsequent mortality [34].

The serum biomarker, calcium-binding protein B (S100B), reflects BBB disruption, glial cell injury, and activation. S100B is used to evaluate brain injury severity and predict outcomes from stroke, traumatic brain injury, encephalopathy, and delirium [35]. A prospective cohort study demonstrated that day three values for predicting 180-day mortality were superior to day one (0.731 vs. 0.611) [36]. Patients with sepsis-associated encephalopathy also had elevated levels. In another observational study of 22 patients with septic shock, delirium was present in ten. The odds ratio for the risk of developing delirium with an S100B > 0.15 μg/L was 18.0. Patients with delirium had higher plasma levels of IL-6. S100B and IL-6 levels were positively correlated [37]. S100B, PAI-1, angiopoietin (Ang)-2, ZO-1, and OCLN are the main biomarkers currently used to evaluate the vascular injury and BBB permeability.

Gut permeability markers

Critically ill patients show an increase in gut permeability, which may trigger a systemic inflammatory response syndrome and multiple organ dysfunction syndromes (MODS) [38]. Plasma zonulin levels were higher in sepsis patients compared to a post-surgical control group or healthy volunteers [39]. In another study, serum levels of intestinal fatty acid-binding protein (I-FABP) were higher in patients with sepsis and higher still in those with septic shock. Serum D-lactic acid levels were also elevated with sepsis but did not differentiate severity. Neither I-FABP nor D-lactic acid could prognosticate [40].

Non-coding RNAs and miRNA

A non-coding RNA (ncRNA) is an RNA molecule transcribed from DNA but not translated into proteins. A microRNA is a small non-coding RNA molecule that functions in RNA silencing and post-transcriptional gene expression regulation. ncRNAs and mRNAs are being studied as sepsis biomarkers. For example, long non-coding metastasis-associated lung adenocarcinoma transcript 1 (lnc-MALAT1) and micro RNA (miR)-125a were increased in sepsis patients compared with healthy controls and positively correlated with APACHE-II score, SOFA score, serum creatinine, CRP, TNF-α, IL-1β, IL-6, and IL-8. The lnc-MALAT1/miR-125a axis was also a predictor of increased 28-day mortality risk [41]. In another study lnc-MALAT1 expression was increased in acute respiratory distress syndrome (ARDS) patients compared to non-ARDS patients (AUROC: 0.674). Nonsurvivors compared to survivors (AUROC: 0.651) and positively correlated with APACHE-II and SOFA scores, CRP, PCT, TNF-α, IL-1β, IL-6, and IL-17 [42]. Long non-coding RNA maternally expressed gene 3 (lnc-MEG3), and the lnc-MEG3/miR-21 axis were increased, while miR-21 expression was decreased in sepsis patients compared with healthy controls. lnc-MEG3 (AUROC: 0.887) and the lnc-MEG3/miR-21 ratio (AUROC: 0.934) had high values for predicting elevated sepsis risk, while miR-21 (AUROC: 0.801) gave excellent predictive value for a reduced sepsis risk [43]. A further study showed miR-125a and miR-125b expressions were elevated in sepsis patients compared with healthy controls and were predictive of sepsis risk—miR-125a (AUROC: 0.749) and miR-125b (AUROC: 0.839). No correlation was seen between miR-125a and CRP, TNF-α, IL-6, IL-17, and IL-23 in however, miR-125b was positively associated with these cytokines. miR-125a failed to predict 28-day mortality risk (AUROC: 0.588) in sepsis patients, whereas miR-125b was superior (AUROC: 0.699) [44].

Membrane receptors, cell proteins, and metabolites

Cell surface receptors are receptors incorporated into the plasma membrane of cells and act on cell signaling by receiving or binding to extracellular molecules. After detecting such molecules, the production of metabolites occurs. In one study, the cluster of differentiation (CD)-13, CD14, CD25, CD64, and human leukocyte antigen (HLA-DR) showed acceptable sensitivity and specificity for mortality prediction (CD13 AUROC:0.824; CD64 0.843; and HLA-DR 0.804) while CD14 and CD25 did not predict mortality [45]. nCD64 expression, in a further study, nCD64, PCT, CRP, and SOFA scores were higher in septic patients, with nCD64 having the highest AUC (0.879) for differentiating a positive microbial culture. This was superior to PCT (0.868), SOFA score (0.701), CRP (0.609), and white blood cell (WBC) count. In predicting 28-day mortality, the combination of nCD64 and SOFA score had an AUROC of 0.91 versus 0.882 for the combination of PCT and SOFA [46].

A meta-analysis of 19 studies enrolling 3012 patients evaluated the value of PCT (AUROC 0.84) and presepsin (0.87 AUROC) for diagnosing sepsis. The pooled sensitivities and specificities were 0.80 and 0.75 for PCT and 0.84 and 0.73 for presepsin [47]. In one study, levels of presepsin, PCT, CRP, and WBC were higher in sepsis patients than in a SIRS group with AUROC values of 0.954 (presepsin), 0.874 (PCT), 0.859 (CRP), and 0.723 (WBC). The cut-off of presepsin for discriminating between sepsis and SIRS was 407 pg/ml, with sensitivity and specificity values of 98.6% and 82.6%, respectively [48]. In a study of septic children, TREM-1 levels were higher in septic shock patients [49].

Hormones and peptide precursors

Adrenomedullin (ADM) is synthesized in different tissues, including the adrenal cortex, kidney, lung, blood vessels, and heart. It has biological properties, including vasodilating, inotropic, diuretic, natriuretic, and bronchodilating. In one study, mid-regional pro adrenomedullin (MR-proADM) was an independent predictor of five different organ failures (respiratory, coagulation, cardiovascular, neurological, and renal), compared to lactate which predicted three (coagulation, cardiovascular and neurological), PCT two (cardiovascular and renal) and CRP (none) [50]. MR-proADM most accurately identified patients with a high likelihood of further disease progression compared to other biomarkers and clinical scores [51]. A total of 1089 individuals with either sepsis (142) or septic shock (977) were included in a randomized controlled study. The MR-proADM level within the first 24 h after sepsis diagnosis was associated with 7-day mortality (AUROC 0.72 and p < 0.001) and 90-day mortality (AUROC 0.71 and p < 0.001). Patients with declining PCT levels but persistently high MR-proADM levels on day-1 or day-4 had a substantially higher mortality risk of 19.1 (8.0–45.9) and 43.1 (10.1–184.0), respectively [52]. Adult patients hospitalized to ICU had their bioactive-ADM levels measured in this retrospective observational study. This study comprised a total of 1867 patients, 632 septic patients, and 267 septic shock patients. The median bioactive-ADM was 74 pg/mL in sepsis patients, 107 pg/mL in septic shock, and 29 pg/mL in non-septic patients. The association of elevated bioactive-ADM and mortality in sepsis patients and the ICU population resulted in O.R.s of 1.23 and 1.22, respectively [53]. In addition, the MR-proADM is potentially removal by continuous renal replacement therapy (CRRT) [54].

N-terminal (N.T.)-prohormone BNP (NT-proBNP) is a non-active prohormone produced by the heart and released in response to changes in intracardiac pressure. Higher levels of NT-proBNP at 24 h after sepsis onset were associated with lower short physical performance battery (SPPB) scores at 12 months and lower handgrip strength at 6-month and 12-month follow-up. NT-proBNP levels during the acute phase of sepsis may thus be a valuable indicator of a greater risk of long-term impairment in physical function and muscle strength in sepsis survivors [55]. In another study, NT-proBNP levels on admission were higher in-hospital non-survivors (7908 pg/mL) compared with survivors (3479 pg/mL). AUROC curves of admission and 72-h NT-proBNP levels for hospital mortality were 0.631 and 0.648, respectively [56].

PCT is produced in the thyroid's C cells and converted to calcitonin, with no PCT released into the bloodstream. During inflammatory processes, PCT is produced directly by stimulating bacterial components or induced by various inflammatory mediators such as IL-6 and TNF-α. PCT and presepsin had similar performance in predicting positive sepsis results with AUROC values of 0.75 and 0.73, respectively [57]. Another investigation gave AUROC values of 0.87 for PCT and 0.78 for presepsin in predicting bacteremia [58]. Plasma levels of presepsin and PCT were progressively higher in sepsis and septic shock than in non-septic patients. Presepsin was superior to PCT in diagnosing severe community-acquired pneumonia [59], while PCT was marginally superior in another study of septic patients admitted to intensive care [60]. On the other hand, MR-proADM had a better predictive value for septic shock. This study concluded that PCT, MR-proADM, and presepsin are complementary biomarkers that could have utility in the management of septic patients. In an intention-to-treat study comparing PCT versus no PCT guidance, there was no significant difference in 28-day mortality (25.6% PCT versus 28.2% no PCT, p = 0.34). The use of procalcitonin did not impact investment decisions as measured by the frequency of therapeutic and diagnostic interventions. [61].

Neutrophil-related biomarkers

High levels of resistin collected on day 1 of ICU admission were associated with an increased likelihood of developing new organ failure, whereas high myeloperoxidase (MPO) levels on day one were associated with an increased risk of developing incident organ failure for clotting and kidney systems [62].

Soluble receptors

Soluble trigger receptor expressed in the myeloid cell-1 (sTREM-1) is a TREM family member. This receptor offers excellent potential as a biomarker for infectious diseases as it can be measured in different biological fluids, including serum, pleural fluid, sputum, and urine [63]. However, a meta-analysis of 2418 patients enrolled in 19 studies showed serum sTREM-1 had only moderate accuracy in diagnosing patients with suspected sepsis [63]. Combining sTREM-1 with clinical variables offered more significant mortality discrimination compared to clinical variables alone [64]. In a multicenter prospective cohort study, soluble tumor necrosis factor receptor type 1 (sTNFR1) levels > 8861 pg/ml predicted 30-day mortality [65].

Patients with sepsis or septic shock displayed higher levels of the soluble form of the urokinase plasminogen activator receptor (suPAR), PCT, and lactate on days 1, 2, 4, and 7 of admission, with lactate and suPAR being the best risk stratifies for suspected infection [66]. Levels of suPAR and PCT levels were higher in sepsis patients than in a SIRS group with AUROC values of 0.89 and 0.82, respectively [67]. Serum sPD-L1 levels were increased in non-survivors compared with survivors with similar prognostic accuracy for 28-day mortality as APACHE-II and SOFA scores [68]. See Tables 1 and 2 for further information, as well as Fig. 1.

Table 1 Different roles of the biomarkers in sepsis
Table 2 Biomarkers for sepsis, septic shock, and sepsis-associated encephalopathy
Fig. 1
figure 1

Sepsis, septic shock, and sepsis-associated encephalopathy biomarkers. The infection triggers a cascade of signaling pathways that activate several transcription factors and promote proinflammatory mediators such as acute-phase proteins, cytokines, chemokines, and antimicrobial peptides necessary to eliminate the invading pathogens. The unbalanced host immune response triggers vascular endothelial damage, increasing gut and BBB permeability, culminating in organ dysfunction. Ang-2 (angiopoietin-2), APP (acute phase proteins), aPPT (activated partial thromboplastin), AST (astrocytes), AT (antithrombin), BBB (blood–brain barrier), C5aR (complement component 5a receptor), CD (cluster of differentiation), CD14-ST (soluble subtype of CD14), CRP (C reactive protein), DAMPs (damage-associated molecular patterns), GFAP (glial fibrillary acidic protein), HMGB-1 (high mobility group box 1), ICAM-1 (intercellular adhesion molecule 1), I-FABP (intestinal fatty acid binding protein), LBP (lipopolysaccharide binding protein), mHLA-DR (monocytic human leukocyte antigen DR), Mo (macrophage), NFL (neurofilament light), NSE (neuron specific enolase), NT-proBNP (N-terminal pro-brain natriuretic peptide), OCLN (occludin), OLG (oligodendrocyte), PAMPs (pathogen-associated molecular patterns), PCT (procalcitonin), PMNL (polymorphonuclear leukocytes), PT (prothrombin), PTX-3 (pentraxin-3), S100B (calcium-binding protein B), sFlt-1 (soluble fms-like tyrosine kinase 1), suPAR (soluble form of the urokinase plasminogen activator receptor), TNFR (tumor necrosis factor receptor type), TREM-1 (triggering receptor expressed on myeloid cells 1), VCAM-1 (vascular cell adhesion molecule 1), ZO-1 (zonula-occluden 1)


Despite significant advances in treating septic patients, this disease continues to be associated with high mortality rates and high long-term cognitive dysfunction. Extensive research in the area is being performed to validate biomarkers, facilitate sepsis diagnosis, and allow an early intervention that, although primarily supportive, can reduce the risk of death. Sepsis sometimes shows a hyperinflammatory response pattern and may be followed by an immunosuppressive phase, during which multiple organ dysfunction is present. A biomarker or a panel of biomarkers could be a new avenue to predict, identify, or provide new approaches to treat sepsis.

Availability of data and material

Not applicable.


  1. 1.

    Arina P, Singer M. Pathophysiology of sepsis. Curr Opin Anaesthesiol. 2021;34(2):77–84.

    CAS  PubMed  Google Scholar 

  2. 2.

    Chakraborty RK, Burns B. Systemic inflammatory response syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2021, StatPearls Publishing LLC.; 2021.

  3. 3.

    Vincent JL, Martin GS, Levy MM. qSOFA does not replace SIRS in the definition of sepsis. Crit Care (Lond, Engl). 2016;20(1):210.

    Google Scholar 

  4. 4.

    Yende S, Kellum JA, Talisa VB, Peck Palmer OM, Chang CH, Filbin MR, Shapiro NI, Hou PC, Venkat A, LoVecchio F, et al. Long-term host immune response trajectories among hospitalized patients with sepsis. JAMA Netw Open. 2019;2(8):e198686.

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    Barichello T, Generoso JS, Dominguini D, Córneo E, Giridharan VV, Sahrapour TA, Simões LR, Rosa MID, Petronilho F, Ritter C, et al. Postmortem evidence of brain inflammatory markers and injury in septic patients: a systematic review. Crit Care Med. 2021.

    Article  PubMed  Google Scholar 

  6. 6.

    Kumar S, Ingle H, Prasad DV, Kumar H. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol. 2013;39(3):229–46.

    CAS  PubMed  Google Scholar 

  7. 7.

    Heckenberg SG, Brouwer MC, van de Beek D. Bacterial meningitis. Handb Clin Neurol. 2014;121:1361–75.

    PubMed  Google Scholar 

  8. 8.

    Sellner J, Täuber MG, Leib SL. Pathogenesis and pathophysiology of bacterial CNS infections. In: Karen LR, Allan RT, editors. Handbook of clinical neurology, vol. 96. Amsterdam: Elsevier; 2010. p. 1–16.

    Google Scholar 

  9. 9.

    Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24(3):557–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95–112.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science (New York, NY). 2010;327(5963):291–5.

    CAS  Google Scholar 

  12. 12.

    Wiersinga WJ, Leopold SJ, Cranendonk DR, van der Poll T. Host innate immune responses to sepsis. Virulence. 2014;5(1):36–44.

    PubMed  Google Scholar 

  13. 13.

    Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ, Wang H. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014;10(6):713–27.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Kigerl KA, de Rivero Vaccari JP, Dietrich WD, Popovich PG, Keane RW. Pattern recognition receptors and central nervous system repair. Exp Neurol. 2014;258:5–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Kataoka H, Kono H, Patel Z, Rock KL. Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. PLoS ONE. 2014;9(8):e104741.

    PubMed  PubMed Central  Google Scholar 

  16. 16.

    Generoso JS, Giridharan VV, Lee J, Macedo D, Barichello T. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry. 2020;10(44462020005021200):1516–4446.

    Google Scholar 

  17. 17.

    Annane D, Sharshar T. Cognitive decline after sepsis. Lancet Respir Med. 2015;3(1):61–9.

    CAS  PubMed  Google Scholar 

  18. 18.

    Barichello T, Sayana P, Giridharan VV, Arumanayagam AS, Narendran B, Della Giustina A, Petronilho F, Quevedo J, Dal-Pizzol F. Long-term cognitive outcomes after sepsis: a translational systematic review. Mol Neurobiol. 2019;56(1):186–251.

    CAS  PubMed  Google Scholar 

  19. 19.

    Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P. The long pentraxin PTX3: a prototypical sensor of tissue injury and a regulator of homeostasis. Immunol Rev. 2017;280(1):112–25.

    CAS  PubMed  Google Scholar 

  20. 20.

    McFadyen JD, Zeller J, Potempa LA, Pietersz GA, Eisenhardt SU, Peter K. C-Reactive protein and its structural isoforms: an evolutionary conserved marker and central player in inflammatory diseases and beyond. Subcell Biochem. 2020;94:499–520.

    CAS  PubMed  Google Scholar 

  21. 21.

    Pierrakos C, Velissaris D, Bisdorff M, Marshall JC, Vincent JL. Biomarkers of sepsis: time for a reappraisal. Crit Care (Lond, Engl). 2020;24(1):287.

    Google Scholar 

  22. 22.

    Yende S, Kellum JA, Talisa VB, Peck Palmer OM, Chang CH, Filbin MR, Shapiro NI, Hou PC, Venkat A, LoVecchio F, et al. Long-term host immune response trajectories among hospitalized patients with sepsis. JAMA Netw Open. 2019;2(8):e198686.

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Caironi P, Masson S, Mauri T, Bottazzi B, Leone R, Magnoli M, Barlera S, Mamprin F, Fedele A, Mantovani A, et al. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. Eur J Clin Invest. 2017;47(1):73–83.

    CAS  PubMed  Google Scholar 

  24. 24.

    Song J, Moon S, Park DW, Cho HJ, Kim JY, Park J, Cha JH. Biomarker combination and SOFA score for the prediction of mortality in sepsis and septic shock: a prospective observational study according to the Sepsis-3 definitions. Medicine. 2020;99(22):e20495.

    PubMed  Google Scholar 

  25. 25.

    Younger JG, Bracho DO, Chung-Esaki HM, Lee M, Rana GK, Sen A, Jones AE. Complement activation in emergency department patients with severe sepsis. Acad Emerg Med Off J Soc Acad Emerg Med. 2010;17(4):353–9.

    Google Scholar 

  26. 26.

    Abe T, Kubo K, Izumoto S, Shimazu S, Goan A, Tanaka T, Koroki T, Saito K, Kawana R, Ochiai H. Complement activation in human sepsis is related to sepsis-induced disseminated intravascular coagulation. Shock (Augusta, Ga). 2020;54(2):198–204.

    CAS  Google Scholar 

  27. 27.

    Matsumoto H, Ogura H, Shimizu K, Ikeda M, Hirose T, Matsuura H, Kang S, Takahashi K, Tanaka T, Shimazu T. The clinical importance of a cytokine network in the acute phase of sepsis. Sci Rep. 2018;8(1):13995.

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Larsson A, Tydén J, Johansson J, Lipcsey M, Bergquist M, Kultima K, Mandic-Havelka A. Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients. Scand J Clin Lab Invest. 2020;80(2):156–61.

    CAS  PubMed  Google Scholar 

  29. 29.

    Matsuura R, Komaru Y, Miyamoto Y, Yoshida T, Yoshimoto K, Hamasaki Y, Nangaku M, Doi K. Different biomarker kinetics in critically ill patients with high lactate levels. Diagnostics (Basel, Switzerland). 2020;10(7):454.

    CAS  Google Scholar 

  30. 30.

    Barichello T, Generoso JS, Collodel A, Petronilho F, Dal-Pizzol F. The blood-brain barrier dysfunction in sepsis. Tissue Barriers. 2021;9(1):1840912.

    PubMed  Google Scholar 

  31. 31.

    Zhao GJ, Li D, Zhao Q, Lian J, Hu TT, Hong GL, Yao YM, Lu ZQ. Prognostic value of plasma tight-junction proteins for sepsis in emergency department: an observational study. Shock. 2016;45(3):326–32.

    CAS  PubMed  Google Scholar 

  32. 32.

    Erikson K, Tuominen H, Vakkala M, Liisanantti JH, Karttunen T, Syrjälä H, Ala-Kokko TI. Brain tight junction protein expression in sepsis in an autopsy series. Crit Care. 2020;24(1):385.

    PubMed  PubMed Central  Google Scholar 

  33. 33.

    Skibsted S, Jones AE, Puskarich MA, Arnold R, Sherwin R, Trzeciak S, Schuetz P, Aird WC, Shapiro NI. Biomarkers of endothelial cell activation in early sepsis. Shock. 2013;39(5):427–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Ikeda M, Matsumoto H, Ogura H, Hirose T, Shimizu K, Yamamoto K, Maruyama I, Shimazu T. Circulating syndecan-1 predicts the development of disseminated intravascular coagulation in patients with sepsis. J Crit Care. 2018;43:48–53.

    CAS  PubMed  Google Scholar 

  35. 35.

    Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6(2):121–38.

    CAS  PubMed  Google Scholar 

  36. 36.

    Wu L, Feng Q, Ai ML, Deng SY, Liu ZY, Huang L, Ai YH, Zhang L. The dynamic change of serum S100B levels from day 1 to day 3 is more associated with sepsis-associated encephalopathy. Sci Rep. 2020;10(1):7718.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Erikson K, Ala-Kokko TI, Koskenkari J, Liisanantti JH, Kamakura R, Herzig KH, Syrjälä H. Elevated serum S-100β in patients with septic shock is associated with delirium. Acta Anaesthesiol Scand. 2019;63(1):69–73.

    CAS  PubMed  Google Scholar 

  38. 38.

    Assimakopoulos SF, Triantos C, Thomopoulos K, Fligou F, Maroulis I, Marangos M, Gogos CA. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment. Infection. 2018;46(6):751–60.

    CAS  PubMed  Google Scholar 

  39. 39.

    Klaus DA, Motal MC, Burger-Klepp U, Marschalek C, Schmidt EM, Lebherz-Eichinger D, Krenn CG, Roth GA. Increased plasma zonulin in patients with sepsis. Biochem Med (Zagreb). 2013;23(1):107–11.

    CAS  Google Scholar 

  40. 40.

    Zhang X, Liu D, Wang Y, Yan J, Yang X. Clinical significance on serum intestinal fatty acid binding protein and D-lactic acid levels in early intestinal injury of patients with sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(5):545–50.

    PubMed  Google Scholar 

  41. 41.

    Liu W, Geng F, Yu L. Long non-coding RNA MALAT1/microRNA 125a axis presents excellent value in discriminating sepsis patients and exhibits positive association with general disease severity, organ injury, inflammation level, and mortality in sepsis patients. J Clin Lab Anal. 2020;34(6):e23222.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Huang X, Zhao M. High expression of long non-coding RNA MALAT1 correlates with raised acute respiratory distress syndrome risk, disease severity, and increased mortality in sepstic patients. Int J Clin Exp Pathol. 2019;12(5):1877–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Na L, Ding H, Xing E, Gao J, Liu B, Wang H, Yu J, Yu C. Lnc-MEG3 acts as a potential biomarker for predicting increased disease risk, systemic inflammation, disease severity, and poor prognosis of sepsis via interacting with miR-21. J Clin Lab Anal. 2020;34(4):e23123.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Zhao D, Li S, Cui J, Wang L, Ma X, Li Y. Plasma miR-125a and miR-125b in sepsis: correlation with disease risk, inflammation, severity, and prognosis. J Clin Lab Anal. 2020;34(2):e23036.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Mahmoodpoor A, Movassaghpour A, Talebi M, Shadvar K, Soleimanpour H. Value of flow cytometry (HLA-DR, CD14, CD25, CD13, CD64) in prediction of prognosis in critically ill septic patients admitted to ICU: a pilot study. J Clin Anesth. 2020;61:109646.

    PubMed  Google Scholar 

  46. 46.

    Yin WP, Li JB, Zheng XF, An L, Shao H, Li CS. Effect of neutrophil CD64 for diagnosing sepsis in emergency department. World J Emerg Med. 2020;11(2):79–86.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care. 2019;7:22.

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Lu B, Zhang Y, Li C, Liu C, Yao Y, Su M, Shou S. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis. Am J Emerg Med. 2018;36(8):1341–5.

    PubMed  Google Scholar 

  49. 49.

    Şen S, Kamit F, İşgüder R, Yazıcı P, Bal Z, Devrim İ, Bayram SN, Karapınar B, Anıl AB, Vardar F. Surface TREM-1 as a Prognostic Biomarker in Pediatric Sepsis. Indian J Pediatr. 2020;88:134–40.

    PubMed  Google Scholar 

  50. 50.

    Andrés C, Andaluz-Ojeda D, Cicuendez R, Nogales L, Martín S, Martin-Fernandez M, Almansa R, Calvo D, Esteban-Velasco MC, Vaquero-Roncero LM, et al. MR- proADM to detect specific types of organ failure in infection. Eur J Clin Invest. 2020;50(6):19.

    Google Scholar 

  51. 51.

    Schuetz P, Hausfater P, Amin D, Amin A, Haubitz S, Faessler L, Kutz A, Conca A, Reutlinger B, Canavaggio P, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Crit Care. 2015;19(377):015–1098.

    Google Scholar 

  52. 52.

    Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, Loeffler M, Kluge S, Nierhaus A, Jaschinski U, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis—a secondary analysis of a large randomised controlled trial. Crit Care (Lond, Engl). 2018;22(1):79.

    Google Scholar 

  53. 53.

    Lundberg OHM, Lengquist M, Spångfors M, Annborn M, Bergmann D, Schulte J, Levin H, Melander O, Frigyesi A, Friberg H. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care (Lond, Engl). 2020;24(1):636.

    Google Scholar 

  54. 54.

    Honore PM, Redant S, De Bels D. Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not. Crit Care (Lond, Engl). 2020;24(1):553.

    Google Scholar 

  55. 55.

    Custodero C, Wu Q, Ghita GL, Anton SD, Brakenridge SC, Brumback BA, Efron PA, Gardner AK, Leeuwenburgh C, Moldawer LL, et al. Prognostic value of NT-proBNP levels in the acute phase of sepsis on lower long-term physical function and muscle strength in sepsis survivors. Crit Care. 2019;23(1):230.

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Varpula M, Pulkki K, Karlsson S, Ruokonen E, Pettilä V. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit Care Med. 2007;35(5):1277–83.

    CAS  PubMed  Google Scholar 

  57. 57.

    Mihajlovic D, Brkic S, Uvelin A, Draskovic B, Vrsajkov V. Use of presepsin and procalcitonin for prediction of SeptiFast results in critically ill patients. J Crit Care. 2017;40:197–201.

    CAS  PubMed  Google Scholar 

  58. 58.

    Leli C, Ferranti M, Marrano U, Al Dhahab ZS, Bozza S, Cenci E, Mencacci A. Diagnostic accuracy of presepsin (sCD14-ST) and procalcitonin for prediction of bacteraemia and bacterial DNAaemia in patients with suspected sepsis. J Med Microbiol. 2016;65(8):713–9.

    CAS  PubMed  Google Scholar 

  59. 59.

    Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, Amigues L, Corne P, Jonquet O, Dupuy AM. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016;6(1):59.

    PubMed  PubMed Central  Google Scholar 

  60. 60.

    Enguix-Armada A, Escobar-Conesa R. García-De La Torre A, De La Torre-Prados MV. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med. 2016;54(1):163–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Gründling M, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176(9):1266–76.

    PubMed  Google Scholar 

  62. 62.

    Bonaventura A, Carbone F, Vecchié A, Meessen J, Ferraris S, Beck E, Keim R, Minetti S, Elia E, Ferrara D, et al. The role of resistin and myeloperoxidase in severe sepsis and septic shock: results from the ALBIOS trial. Eur J Clin Investig. 2020;50:e1333.

    Google Scholar 

  63. 63.

    Cao C, Gu J, Zhang J. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious diseases. Front Med. 2017;11(2):169–77.

    PubMed  Google Scholar 

  64. 64.

    Wright SW, Lovelace-Macon L, Hantrakun V, Rudd KE, Teparrukkul P, Kosamo S, Liles WC, Limmathurotsakul D, West TE. sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middle-income country. BMC Med. 2020;18(1):159.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Anderson BJ, Calfee CS, Liu KD, Reilly JP, Kangelaris KN, Shashaty MGS, Lazaar AL, Bayliffe AI, Gallop RJ, Miano TA, et al. Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study. Crit Care (Lond, Engl). 2019;23(1):400.

    Google Scholar 

  66. 66.

    Casagranda I, Vendramin C, Callegari T, Vidali M, Calabresi A, Ferrandu G, Cervellin G, Cavazza M, Lippi G, Zanotti I, et al. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Intern Emerg Med. 2015;10(6):725–30.

    PubMed  Google Scholar 

  67. 67.

    Sharma A, Ray S, Mamidipalli R, Kakar A, Chugh P, Jain R, Ghalaut MS, Choudhury S. A comparative study of the diagnostic and prognostic utility of soluble urokinase-type plasminogen activator receptor and procalcitonin in patients with sepsis and systemic inflammation response syndrome. Indian J Crit Care Med Peer Review Off Publ Indian Soc Crit Care Med. 2020;24(4):245–51.

    CAS  Google Scholar 

  68. 68.

    Liu M, Zhang X, Chen H, Wang G, Zhang J, Dong P, Liu Y, An S, Wang L. Serum sPD-L1, upregulated in sepsis, may reflect disease severity and clinical outcomes in septic patients. Scand J Immunol. 2017;85(1):66–72.

    CAS  PubMed  Google Scholar 

  69. 69.

    Yeh CF, Wu CC, Liu SH, Chen KF. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care. 2019;9(1):5.

    PubMed  PubMed Central  Google Scholar 

  70. 70.

    Zhang Y, Feng Q, Zhou S, Chen H. Downregulation of serum survivin correlates with increased inflammation, enhanced disease severity and worse prognosis in sepsis patients. Medicine. 2020;99(28):0000000000020272.

    Google Scholar 

  71. 71.

    Hoppensteadt D, Tsuruta K, Hirman J, Kaul I, Osawa Y, Fareed J. Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2015;21(2):120–7.

    PubMed  Google Scholar 

  72. 72.

    Hamed S, Behnes M, Pauly D, Lepiorz D, Barre M, Becher T, Lang S, Akin I, Borggrefe M, Bertsch T, et al. Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions. BMC Infect Dis. 2017;17(1):554.

    PubMed  PubMed Central  Google Scholar 

  73. 73.

    Tian R, Wang X, Pan T, Li R, Wang J, Liu Z, Chen E, Mao E, Tan R, Chen Y, et al. Plasma PTX3, MCP1 and Ang2 are early biomarkers to evaluate the severity of sepsis and septic shock. Scand J Immunol. 2019;90(6):7.

    Google Scholar 

  74. 74.

    Barre M, Behnes M, Hamed S, Pauly D, Lepiorz D, Lang S, Akin I, Borggrefe M, Bertsch T, Hoffmann U. Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin-6 in the sepsis-3 era. J Crit Care. 2018;43:21–8.

    CAS  PubMed  Google Scholar 

  75. 75.

    Karlsson S, Pettilä V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. 2008;34(6):1046–53.

    CAS  PubMed  Google Scholar 

  76. 76.

    Karakike E, Adami ME, Lada M, Gkavogianni T, Koutelidakis IM, Bauer M, Giamarellos-Bourboulis EJ, Tsangaris I. Late peaks of hmgb1 and sepsis outcome: evidence for synergy with chronic inflammatory disorders. Shock. 2019;52(3):334–9.

    CAS  PubMed  Google Scholar 

  77. 77.

    Lerman YV, Lim K, Hyun YM, Falkner KL, Yang H, Pietropaoli AP, Sonnenberg A, Sarangi PP, Kim M. Sepsis lethality via exacerbated tissue infiltration and TLR-induced cytokine production by neutrophils is integrin α3β1-dependent. Blood. 2014;124(24):3515–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. 78.

    Sarangi PP, Hyun YM, Lerman YV, Pietropaoli AP, Kim M. Role of β1 integrin in tissue homing of neutrophils during sepsis. Shock (Augusta, Ga). 2012;38(3):281–7.

    CAS  Google Scholar 

  79. 79.

    Fang Y, Li C, Shao R, Yu H, Zhang Q. The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: a prospective observational study. Thromb Res. 2018;171:149–54.

    CAS  PubMed  Google Scholar 

  80. 80.

    Yao B, Zhang LN, Ai YH, Liu ZY, Huang L. Serum S100β is a better biomarker than neuron-specific enolase for sepsis-associated encephalopathy and determining its prognosis: a prospective and observational study. Neurochem Res. 2014;39(7):1263–9.

    CAS  PubMed  Google Scholar 

  81. 81.

    Mikacenic C, Hahn WO, Price BL, Harju-Baker S, Katz R, Kain KC, Himmelfarb J, Liles WC, Wurfel MM. Biomarkers of endothelial activation are associated with poor outcome in critical illness. PLoS ONE. 2015;10(10):e0141251.

    PubMed  PubMed Central  Google Scholar 

  82. 82.

    Crenn P, Neveux N, Chevret S, Jaffray P, Cynober L, Melchior JC, Annane D. Plasma L-citrulline concentrations and its relationship with inflammation at the onset of septic shock: a pilot study. J Crit Care. 2014;29(2):315.e311-316.

    Google Scholar 

  83. 83.

    Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christman BW, Wheeler AP, Bernard GR, Summar ML. Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis. Crit Care. 2013;17(1):1–8.

    Google Scholar 

  84. 84.

    Zhu X. MiR-125b but not miR-125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients. J Clin Lab Anal. 2020;34(3):e23094.

    PubMed  Google Scholar 

  85. 85.

    Gui F, Peng H, Liu Y. Elevated circulating lnc-ANRIL/miR-125a axis level predicts higher risk, more severe disease condition, and worse prognosis of sepsis. J Clin Lab Anal. 2019;33(6):e22917.

    PubMed  PubMed Central  Google Scholar 

  86. 86.

    Westhoff D, Engelen-Lee JY, Hoogland ICM, Aronica EMA, van Westerloo DJ, van de Beek D, van Gool WA. Systemic infection and microglia activation: a prospective postmortem study in sepsis patients. Immun Ageing. 2019;16(18):019–0158.

    Google Scholar 

  87. 87.

    Ehler J, Petzold A, Wittstock M, Kolbaske S, Gloger M, Henschel J, Heslegrave A, Zetterberg H, Lunn MP, Rommer PS, et al. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy—a prospective, pilot observational study. PLoS ONE. 2019;14(1):e0211184.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88.

    Anderson BJ, Reilly JP, Shashaty MGS, Palakshappa JA, Wysoczanski A, Dunn TG, Kazi A, Tommasini A, Mikkelsen ME, Schweickert WD, et al. Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis. J Crit Care. 2016;36:18–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Şen S, Kamit F, İşgüder R, Yazıcı P, Bal Z, Devrim İ, Bayram SN, Karapınar B, Anıl AB, Vardar F. Surface TREM-1 as a Prognostic Biomarker in Pediatric Sepsis. Indian J Pediatr. 2020;23(10):020–03355.

    Google Scholar 

  90. 90.

    Aksaray S, Alagoz P, Inan A, Cevan S, Ozgultekin A. Diagnostic value of sTREM-1 and procalcitonin levels in the early diagnosis of sepsis. North Clin Istanb. 2016;3(3):175–82.

    PubMed  Google Scholar 

  91. 91.

    Brenner T, Uhle F, Fleming T, Wieland M, Schmoch T, Schmitt F, Schmidt K, Zivkovic AR, Bruckner T, Weigand MA, et al. Soluble TREM-1 as a diagnostic and prognostic biomarker in patients with septic shock: an observational clinical study. Biomark Biochem Ind Expos Response Susceptibility Chem. 2017;22(1):63–9.

    CAS  Google Scholar 

  92. 92.

    Spoto S, Cella E, de Cesaris M, Locorriere L, Mazzaroppi S, Nobile E, Lanotte AM, Pedicino L, Fogolari M, Costantino S, et al. Procalcitonin and MR-proadrenomedullin combination with SOFA and qSOFA Scores for Sepsis diagnosis and prognosis: a diagnostic algorithm. Shock (Augusta, Ga). 2018;50(1):44–52.

    CAS  Google Scholar 

  93. 93.

    Yang Y, Liang S, Geng J, Wang Q, Wang P, Cao Y, Li R, Gao G, Li L. Development of a nomogram to predict 30-day mortality of patients with sepsis-associated encephalopathy: a retrospective cohort study. J Intensive Care. 2020;8(45):020–00459.

    Google Scholar 

  94. 94.

    Bonaventura A, Carbone F, Vecchié A, Meessen J, Ferraris S, Beck E, Keim R, Minetti S, Elia E, Ferrara D, et al. The role of resistin and myeloperoxidase in severe sepsis and septic shock: Results from the ALBIOS trial. Eur J Clin Invest. 2020;50(10):13.

    Google Scholar 

  95. 95.

    Maruchi Y, Tsuda M, Mori H, Takenaka N, Gocho T, Huq MA, Takeyama N. Plasma myeloperoxidase-conjugated DNA level predicts outcomes and organ dysfunction in patients with septic shock. Crit Care. 2018;22(1):018–2109.

    Google Scholar 

  96. 96.

    Karampela I, Christodoulatos GS, Kandri E, Antonakos G, Vogiatzakis E, Dimopoulos G, Armaganidis A, Dalamaga M. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: a prospective observational study. Cytokine. 2019;119:62–70.

    CAS  PubMed  Google Scholar 

  97. 97.

    Saboktakin L, Bilan N, Ghalehgolab Behbahan A, Poorebrahim S. Relationship between resistin levels and sepsis among children under 12 years of age: a case control study. Front Pediatr. 2019;7:355.

    PubMed  PubMed Central  Google Scholar 

  98. 98.

    Ritter C, Tomasi CD, Dal-Pizzol F, Pinto BB, Dyson A, de Miranda AS, Comim CM, Soares M, Teixeira AL, Quevedo J, et al. Inflammation biomarkers and delirium in critically ill patients. Crit Care. 2014;18(3):1–6.

    Google Scholar 

  99. 99.

    Feng Q, Wei WQ, Chaugai S, Leon BGC, Mosley JD, Leon DAC, Jiang L, Ihegword A, Shaffer CM, Linton MF, et al. Association between low-density lipoprotein cholesterol levels and risk for sepsis among patients admitted to the hospital with infection. JAMA Netw Open. 2019;2(1):e187223.

    PubMed  PubMed Central  Google Scholar 

  100. 100.

    Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33(8):1688–93.

    CAS  PubMed  Google Scholar 

  101. 101.

    Cirstea M, Walley KR, Russell JA, Brunham LR, Genga KR, Boyd JH. Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care. 2017;38:289–94.

    CAS  PubMed  Google Scholar 

  102. 102.

    Takegawa R, Kabata D, Shimizu K, Hisano S, Ogura H, Shintani A, Shimazu T. Serum albumin as a risk factor for death in patients with prolonged sepsis: an observational study. J Crit Care. 2019;51:139–44.

    CAS  PubMed  Google Scholar 

  103. 103.

    Sui YD, Xin WN, Feng LL. Comparison of the clinical application values of PCT, hs-CRP and SAA detection in the early diagnosis of sepsis. Pak J Med Sci. 2020;36(7):1683–7.

    PubMed  PubMed Central  Google Scholar 

  104. 104.

    Hou X, Liu C, Lian H, Xu Z, Ma L, Zang X, Sun J, Jia K, Cui L. The value of neutrophil gelatinase-associated lipocalin and citrullinated alpha enolase peptide-1 antibody in diagnosis, classification, and prognosis for patients with sepsis. Medicine. 2020;99(34):0000000000021893.

    Google Scholar 

  105. 105.

    Zhang H, Wang X, Zhang Q, Xia Y, Liu D. Comparison of procalcitonin and high-sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatr. 2017;17(1):017–0566.

    Google Scholar 

  106. 106.

    Lin R, Hu H, Li L, Chen G, Luo L, Rao P. The potential of microRNA-126 in predicting disease risk, mortality of sepsis, and its correlation with inflammation and sepsis severity. J Clin Lab Anal. 2020;34(9):2.

    Google Scholar 

  107. 107.

    Zeng Q, Wu J, Yang S. Circulating lncRNA ITSN1-2 is upregulated, and its high expression correlates with increased disease severity, elevated inflammation, and poor survival in sepsis patients. J Clin Lab Anal. 2019;33(4):25.

    Google Scholar 

  108. 108.

    Piazza O, Russo E, Cotena S, Esposito G, Tufano R. Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis. Br J Anaesth. 2007;99(4):518–21.

    CAS  PubMed  Google Scholar 

  109. 109.

    Crenn P, Neveux N, Chevret S, Jaffray P, Cynober L, Melchior JC, Annane D. Plasma L-citrulline concentrations and its relationship with inflammation at the onset of septic shock: a pilot study. J Crit Care. 2014;29(2):26.

    Google Scholar 

  110. 110.

    Chen J, He Y, Zhou L, Deng Y, Si L. Long non-coding RNA MALAT1 serves as an independent predictive biomarker for the diagnosis, severity and prognosis of patients with sepsis. Mol Med Rep. 2020;21(3):1365–73.

    CAS  PubMed  Google Scholar 

  111. 111.

    Zhao D, Li S, Cui J, Wang L, Ma X, Li Y. Plasma miR-125a and miR-125b in sepsis: correlation with disease risk, inflammation, severity, and prognosis. J Clin Lab Anal. 2020;34(2):23036.

    Google Scholar 

  112. 112.

    Ehler J, Saller T, Wittstock M, Rommer PS, Chappell D, Zwissler B, Grossmann A, Richter G, Reuter DA, Nöldge-Schomburg G, et al. Diagnostic value of NT-proCNP compared to NSE and S100B in cerebrospinal fluid and plasma of patients with sepsis-associated encephalopathy. Neurosci Lett. 2019;692:167–73.

    CAS  PubMed  Google Scholar 

  113. 113.

    Aksaray S, Alagoz P, Inan A, Cevan S, Ozgultekin A. Diagnostic value of sTREM-1 and procalcitonin levels in the early diagnosis of sepsis. North Clin Istanb. 2017;3(3):175–82.

    PubMed  PubMed Central  Google Scholar 

  114. 114.

    Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet (Lond, Engl). 1993;341(8844):515–8.

    CAS  Google Scholar 

  115. 115.

    Saboktakin L, Bilan N, Ghalehgolab Behbahan A, Poorebrahim S. Relationship between resistin levels and sepsis among children under 12 years of age: a case control study. Front Pediatr. 2019;7:355.

    PubMed  PubMed Central  Google Scholar 

Download references


This work was supported by the Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), USA (T.B.); the Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC) (T.B., JSG, and FDP), Brazil; the Alzheimer's Association and U.S. National Institute of Health/National Institute on Aging (NIH/NIA (T.B.).


The Alzheimer’s Association Grant number AARGDNTF-19-619645 and U.S. National Institute of Health/National Institute on Aging (NIH/NIA Grant (1RF1AG072491-01) (T.B.); MCTIC/CNPq/FNDCT/MS/SCTIE/Decit Nº 401263/2020-7 (FD-P)).

Author information




Conceptualization: TB, MS, and FD-P; Writing—original draft: TB and JSG. Writing (review and editing): TB, JSG, MS, and FD-P. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tatiana Barichello.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Barichello, T., Generoso, J.S., Singer, M. et al. Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review. Crit Care 26, 14 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Biomarker
  • Systemic inflammatory response
  • Sepsis
  • Septic shock
  • Sepsis-associated encephalopathy